Plain-English translation of NCT05562960 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing plasmapheresis—a procedure that filters your blood to remove harmful antibodies—in people with ALS who have a specific autoantibody called anti-NRIP. Researchers believe this treatment might help slow down the disease in this particular group of patients by removing the antibodies that may be causing damage to nerve cells.
Some people with ALS have a specific antibody in their blood that appears to make their disease worse. This treatment aims to help this smaller group of patients by removing those harmful antibodies, which other treatments currently cannot do.
You would receive plasmapheresis treatments, which involve having your blood drawn, filtered through a machine to remove the harmful antibodies, and then returned to your body. You would attend multiple visits for these procedures and have regular blood tests and examinations to see how the treatment affects your symptoms and disease progression.
AI-generated summary from trial data · Jun 1, 2026 · Not medical advice
Taiwan
National Taiwan University Hospital
Enrollment target
~5 participants
Started
May 2023
Primary completion
March 2025
Age range
20 Years and older
Last updated on clinicaltrials.gov in July 2026.